Physician profile
Don J Park
NPI 1285714352
$34,658.04
in general payments reported to CMS, 2019-2025
24 companies · $6,378 in 2025
The $6,378 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,802 · 2020: $5,749 · 2021: $8,797 · 2022: $1,240 · 2023: $2,672 · 2024: $4,020 · 2025: $6,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Travel and Lodging: $588 · Food and Beverage: $429 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,805.00 |
| Travel and Lodging | $588.01 |
| Food and Beverage | $428.71 |
| Education | $247.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $8,109.87 | 2023-2025 | Calquence, Tagrisso, Imfinzi |
| Celgene Corporation | $7,223.00 | 2019-2020 | |
| Acceleron Pharma, INC. | $3,960.00 | 2020 | |
| Pfizer INC. | $3,764.54 | 2019-2021 | |
| Syndax Pharmaceuticals, INC. | $3,637.11 | 2025 | Revuforj |
| Dova Pharmaceuticals | $3,040.00 | 2021 | |
| Morphosys, US INC. | $1,140.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $1,037.50 | 2021 | |
| Alphatec Spine, INC | $840.00 | 2021 | |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Incyte Corporation | $254.97 | 2022-2024 | |
| Genentech USA, INC. | $205.08 | 2019 | |
| Astellas Pharma US INC | $164.11 | 2019-2024 | Xospata |
| Abbvie INC. | $117.90 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $92.99 | 2025 | Soliris |
| Merck Sharp & Dohme LLC | $24.97 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $15.34 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.75 | 2019 | |
| Lilly USA, LLC | $14.67 | 2020 | |
| Seagen INC. | $13.61 | 2020 | |
| Gilead Sciences, INC. | $13.43 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.80 | 2019 | |
| Adc Therapeutics America, INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.